Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-01-10 Fund Information / Fact…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
112年12月營業收入
Fund Information / Factsheet Classification · 85% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 美時, presented in a tabular format with explanations about accounting standards and reporting practices. It contains no detailed financial statements, management discussion, or comprehensive analysis. The length is short (781 characters), and it appears to be a brief financial data summary rather than a full report or announcement. It does not fit the description of Annual Report, Interim Report, Earnings Release, or other detailed filings. Given the concise nature and summary style, it best fits the Fund Information / Factsheet (FS) category, which is for brief summaries of key company financials and facts.
2024-01-10 Chinese
112年12月內部人持股異動(事後)
Major Shareholding Notification Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, general managers, and major shareholders. It includes data on shares held, increases, decreases, and trust shares, which is typical of insider shareholding disclosures. There is no indication of financial statements, earnings data, management discussion, or meeting materials. The content matches the description of a Major Shareholding Notification, which reports changes in significant share ownership levels. The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2024-01-09 Chinese
112年12月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, senior management, and related parties, showing their current holdings, pledged shares, and related percentages. It includes specific names, titles, and share counts. The content focuses on insider shareholdings and does not contain financial statements, earnings data, or report summaries. It is not an announcement of a report but a disclosure of insider shareholdings. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions or holdings by company directors and executives. The document length is 4310 characters, which is sufficient for a detailed insider shareholding report. Therefore, the appropriate classification is DIRS with high confidence.
2024-01-09 Chinese
111年企業社會責任報告書
Report Publication Announcement Classification · 95% confidence The document is very short (1328 characters) and appears to be a summary or index entry related to a sustainability report for the company Lotus Pharm (code 1795). It includes metadata such as reporting period (111/01/01~111/12/31, which corresponds to a full year), the standards used (GRI standards), third-party verification by an accounting firm, and links to the report files in both Chinese and English. The document does not contain the actual sustainability report content but rather provides links and metadata about the report. This fits the pattern of a Report Publication Announcement (RPA), as it announces the availability of the sustainability report rather than containing the full report itself. Therefore, the correct classification is RPA with high confidence.
2023-12-27 Chinese
美時公告學名藥Midostaurin Capsules與諾華達成 美國市場和解協議
Regulatory Filings Classification · 95% confidence The document is a short announcement (922 characters) from a listed company (美時) reporting a settlement agreement with Novartis regarding a generic drug Midostaurin Capsules in the US market. It includes details about the event date, company name, relationship, and impact on shareholder rights or stock price. There are no financial statements, detailed financial data, or comprehensive report content. The document is a regulatory announcement about a material event affecting the company, fitting the description of a Regulatory Filing (RNS) rather than a full report or presentation. It is not a report publication announcement since it does not mention any report being attached or published.
2023-12-13 Chinese
112年11月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (美時) providing information about fund loans and endorsement guarantees for the current and previous month, including limits and balances. It is very short (620 characters) and contains tabular data about financial exposures but does not include comprehensive financial statements or detailed analysis. It appears to be a regulatory disclosure or compliance update rather than a full financial report or announcement of a meeting or vote. There is no indication of an annual or interim report, audit report, earnings release, or other specific filings. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other categories.
2023-12-08 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.